These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 30882636

  • 1. Comparison of the psychometric properties of the EQ-5D-3L and SF-6D in the general population of Chengdu city in China.
    Zhao L, Liu X, Liu D, He Y, Liu Z, Li N.
    Medicine (Baltimore); 2019 Mar; 98(11):e14719. PubMed ID: 30882636
    [Abstract] [Full Text] [Related]

  • 2. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C, Ferrara P, Gerónimo-Pardo M.
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of EuroQol-5D-3L and Short Form-6D Utility Scores in Family Caregivers of Colorectal Cancer Patients: A Cross-Sectional Survey in China.
    Sun CY, Liu Y, Zhou LR, Wang MS, Zhao XM, Huang WD, Liu GX, Zhang X.
    Front Public Health; 2021 Jun; 9():742332. PubMed ID: 34660519
    [Abstract] [Full Text] [Related]

  • 6. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH, Wong CKH, Cheung JPY.
    Spine (Phila Pa 1976); 2019 Jun 01; 44(11):E679-E686. PubMed ID: 30475342
    [Abstract] [Full Text] [Related]

  • 7. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F, Carotti M, Ciapetti A, Gasparini S, Grassi W.
    Clin Exp Rheumatol; 2011 Jun 01; 29(4):661-71. PubMed ID: 21813061
    [Abstract] [Full Text] [Related]

  • 8. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
    Kontodimopoulos N, Stamatopoulou E, Brinia A, Talias MA, Ferreira LN.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec 01; 18(6):667-675. PubMed ID: 30048194
    [Abstract] [Full Text] [Related]

  • 9. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
    Kangwanrattanakul K.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug 01; 21(4):765-774. PubMed ID: 32981380
    [Abstract] [Full Text] [Related]

  • 10. Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
    Mukuria C, Rowen D, Acaster S, McGarry LJ, Lou Y, Sosnay PR, Quittner AL.
    J Patient Rep Outcomes; 2024 Feb 28; 8(1):24. PubMed ID: 38416239
    [Abstract] [Full Text] [Related]

  • 11. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
    Xu RH, Dong D, Luo N, Wong EL, Wu Y, Yu S, Yang R, Liu J, Yuan H, Zhang S.
    Eur J Health Econ; 2021 Jun 28; 22(4):547-557. PubMed ID: 33761029
    [Abstract] [Full Text] [Related]

  • 12. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D.
    Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, Shimozuma K.
    Qual Life Res; 2016 Mar 28; 25(3):707-19. PubMed ID: 26303761
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH, Lang BHH, Yu HMS, Lam CLK.
    Patient; 2017 Aug 28; 10(4):447-454. PubMed ID: 28224296
    [Abstract] [Full Text] [Related]

  • 16. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients.
    Wu J, Han Y, Zhao FL, Zhou J, Chen Z, Sun H.
    Health Qual Life Outcomes; 2014 Oct 25; 12():156. PubMed ID: 25343944
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.